Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 38

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
) 
     (36.6)%
  
    Non-Clinical R&D and CMC 

    OVATION 
     913  
     405  
     508  
     125.4%
  
    PlaCCine Vaccine 
     -  
     1,215  
     (1,215) 
     -%
  
    Manufacturing (CMC) 
     406  
     339  
     67  
     19.8%
  
    Subtotal 
     1,319  
     1,959  
     (640) 
     (32.7)%
  
    Research and development expenses 
     2,165  
     3,294  
     (1,129) 
     (34.3)%
  
    General and administrative expenses 
     1,980  
     1,717  
     263  
     15.3%
  
    Total operating expenses 
     4,145  
     5,011  
     (866) 
     (17.3)%
  
    Loss from operations 
    $(4,145) 
    $(5,011) 
    $(866) 
     (17.3)%

24

Research
and Development Expenses

Research
and development (“R&D”) expenses were $2.2 million in the first quarter of 2025 compared to $3.3 million in same period
of 2024. Clinical costs associated with the OVATION program were $0.2 million in the first quarter of 2025 compared to $0.3 million in 2024. Clinical costs
associated with the PlaCCine vaccine trial were $58,000 in the first quarter of 2025 compared to $0.6 million in the first quarter of
2024. Other clinical and regulatory costs were $0.6 million the first quarter of 2025 compared to $0.5 million in the same period of
2024. R&D costs associated with the development of IMNN-001 to support the OVATION program were $0.9 million in the first quarter
of 2025 compared to $0.4 million in same period of 2024. The development of the PLACCINE DNA vaccine technology platform was $1.2 million
in the first quarter of 2024. CMC costs